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Abstract
Revascularization of the extracranial carotid arteries is a commonly performed surgical procedure to
prevent stroke. Open surgery (i.e., carotid endarterectomy [CEA]) is a well-established stroke
prevention procedure but is being ‘challenged’ by a less invasive percutaneous procedure (i.e., carotid
artery stent [CAS] placement). Clinical trials comparing CAS and CEA for average-surgical-risk
patients have demonstrated mixed results, whereas the data for CAS compared with CEA in high-
surgical-risk patients have demonstrated non-inferiority. The impending Carotid Revascularization
Endarterectomy Versus Stenting Trial (CREST) results will have a major impact on the utility of CAS
relative to CEA in average-surgical-risk patients.
Introduction and context
Stroke is the third leading cause of death in the US after
coronary artery disease and cancer and it is the leading
cause of disability. There are two main types of stroke:
ischemic and hemorrhagic. Ischemic stroke is most often
caused by atherothrombotic emboli. Extracranial ather-
osclerotic carotid artery disease accounts for slightly
more than half of the 731,000 strokes per year in the US.
Hemorrhagic stroke includes primary cerebral hemor-
rhages or hemorrhage secondary to an ischemic event.
Cerebrovascular events are classified as transient ischemic
attacks (TIAs) or as strokes. A TIA is a transient episode of
neurological dysfunction caused by focal brain, spinal
cord, or retinal ischemia, without acute infarction [1]. An
ischemic stroke is defined as an infarction of central
nervous system tissue [1]. The current definitions of TIA
and stroke no longer include a duration requirement.
Ischemic strokes may be either symptomatic or silent.
Symptomatic ischemic strokes are manifested by clinical
signs of focal or global cerebral, spinal, or retinal dys-
function caused by central nervous system infarction.
Hemispheric or focal symptoms relate to a single carotid
distribution, causing contralateral hemiparesis or hemi-
paresthesia, aphasia, and/or ipsilateral monocular blind-
ness (amaurosis fugax). Non-hemispheric symptoms that
often occur with vertebrobasilar insufficiency include
dysarthria, diplopia, vertigo, syncope, and/or transient
confusion.A silentstrokeis a documented central nervous
system infarction that was asymptomatic.
Carotid endarterectomy (CEA) is the currently estab-
lished surgical procedure for stroke prevention in
patients with extracranial carotid artery disease. Some
of CEA’s technical issues such as the benefits of an
intraoperative shunt or of a patch closure versus primary
repair continue to be debated. The comparability of data
from highly selected patient populations enrolled in
clinical trials of CEA with results obtained in everyday
practice has been questioned [2]. There were markedly
higher mortality rates in Medicare patients who under-
went CEA at clinical trial hospitals than in the selected
patients treated in clinical trials. Caution is advised in
translating the efficacy of carefully controlled studies of
CEA to effectiveness in everyday practice [2].
Therehasbeensignificantvariabilityorheterogeneityinthe
reporting of CEA outcomes in the literature, making
comparison of studies difficult and confusing. In a meta-
analysis of CEA in symptomatic patients (n = 51 studies),
the strongest predictor of stroke or death was who
(neurologist or surgeon) performed the post-operative
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operative patients, the risk of 30-day stroke and death
was 7.7%, but when a single author who was a surgeon
performed the evaluation, the reported risk was only 2.3%.
ThereisastrongbiasinfavorofCEAinthecurrentliterature
comparing Medicare or specialty outcomes data [4-6]. The
bias is one of ascertainment; that is, independent neuro-
logical examination is mandated for reimbursement for
most carotid artery stent (CAS) procedures but is rarely
done for CEA. To obtain Medicare reimbursement, all but a
very few CAS procedures must conform to US Food and
Drug Administration (FDA) protocols, which require
independent neurological examination. This independent
neurological examination is not required for CEA reimbur-
sement by Medicare. Performing an independent neurolo-
gical examination markedly increases the number of events
that are detected following a procedure. When comparing
CEA and CAS, it is critical that the methodology for
detecting events (the ascertainment of events) is similar, or
the outcomes will be unfairly slanted.
Recent advances
High risk for carotid endarterectomy
Patients with high-surgical-risk features (Table 1) treated
with CAS have been proven to have outcomes ‘non-
inferior’ to CEA in SAPPHIRE (Stenting and Angioplasty
with Protection of Patients with High Risk for Endarter-
ectomy), a randomized controlled trial (Figure 1) [7].
Three-year outcomes have confirmed the durability of the
CAS [8]. Additional supporting peer-reviewed and pub-
lished evidence include a meta-analysis [9] and multiple
pre-market [10-18] and post-market [19-23] surveillance
trials. Additionally, a multi-specialty endorsed profes-
sional society document from the American College of
Cardiology (ACC)is consistent withthe conclusions of the
randomized controlled trial (SAPPHIRE) and supports the
benefit of CAS in patients with high-risk features for both
symptomatic (>50% stenosis) and asymptomatic (>80%
stenosis) patients [24].
Recently, three very large, post-market surveillance trials
evaluating CAS in a ‘real-world’ environment were
published. The primary objective of the SAPPHIRE
World-Wide (SAPPHIRE WW) post-market approval
registry was to evaluate 30-day outcomes after CAS was
performed in high-surgical-risk patients by CAS operators
of varying experience [20]. Notably, independent neuro-
logical assessment was employed for outcomes assess-
ment. The investigators reported 30-day safety and
efficacy outcomes in 2,001 symptomatic and asympto-
matic high-surgical-risk patients treated by carotid stent
operators with varying clinical experience. The overall,
independently adjudicated, 30-day stroke and death rate
forCASin2,001high-surgical-riskpatientswas4.0% [20].
The results of more than 6,000 high-surgical-risk patients
treated by CAS operators with varying levels of exp-
erience in two large prospective, multi-center, FDA-
mandated post-market surveillance trials (Emboshield
and Xact Post-Approval Carotid Stent Trial [EXACT] [n =
2,145] and Carotid Acculink/Accunet Post-Approval
Trial to Uncover Unanticipated or Rare Events-2
Table 1. Carotid artery stent high-surgical-risk features
Anatomic features Comorbid conditions
Surgically inaccessible lesions at or above C2 spinal level or below
the clavicle
Age of at least 75/80 years
Previous neck or head radiation therapy or surgery that included the
area of stenosis/repair or ipsilateral radical neck dissection
Congestive heart failure (New York Heart Association class III/IV)
Spinal immobility of the neck due to cervical arthritis or other
cervical disorders
Unstable angina (Canadian Cardiovascular System class III/IV)
Restenosis after a previous or unsuccessful attempt of carotid
endarterectomy
Left main/at least two-vessel coronary disease
Contralateral laryngeal palsy Recent heart attack (<30 days)
Presence of a tracheostoma Left ventricular ejection fraction ≤30%
Contralateral carotid occlusion Requirement for heart surgery within 30 days
Severe lung disease
Severe renal disease
Figure 1. SAPPHIRE randomized controlled trial, demonstrating
non-inferiority for the stent compared with surgery in high-
surgical-risk patients
CEA, carotid endarterectomy; C.I., confidence interval.
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demonstrated excellent outcomes [23]. Both trials
included independent neurological assessment of out-
comes to reinforce the rigor for ascertaining adverse
events. The overall rates of incidence of 30-day stroke
and death were 4.1% for the 2,145 EXACT patients and
only 3.4% for the 4,175 CAPTURE-2 patients. Impor-
tantly, for patients who would have been comparable to
patients included in the 2006 American Heart Associa-
tion (AHA) published guidelines (<80 years of age) [25],
the CAS results met the threshold recommendations for
30-daystrokeanddeathrateat5.3%(benchmarkforCEA
≤6%) for symptomatic patients (i.e., those with ≥50%
stenosis) and 2.9% (benchmark for CEA ≤3%) for
asymptomatic patients (i.e., those with ≥80% stenosis)
(Figure 2) [23]. These studies demonstrate equipoise for
CAS and CEA in community settings on the basis of data
collected during the decade of the 1990s with the large
CEA versus best medical therapy trials, and the AHA
expert consensus panel suggested that the perioperative
risk of stroke and death should not exceed 3% for
asymptomatic patients, 6% for symptomatic patients, or
10% for repeat CEA [25,26].
Published data have suggested that very old patients
(≥75-80 years of age) are at increased risk for not only a
higher complication rate of CEA [2,27,28] but also worse
outcomes for CAS [11,23,29,30]. However, three peer-
reviewed manuscripts published in the past year have
reported excellent outcomesi nh i g h - s u r g i c a l - r i s k
patients ≥80 years of age undergoing CAS [31-33]. The
very favorable overall 30-day stroke and death rates with
independent neurological assessment in these octogen-
arians were 3.3%, 2.7%, and 0.8% [31-33]. The authors
emphasized the importance of operator experience and
careful case selection to avoid difficult aortic arch access,
excessive lesion tortuosity, and heavy calcification [30].
The improved outcomes for octogenarians are consistent
with the data reported in the CAPTURE-2 and EXACT
trials demonstrating reduced CAS complications with
expanding operator experience. The published peer-
reviewed evidence does not support denying CAS to
very old patients but does show that the best results are
obtained with careful patient selection and experienced
operators.
Low- or average-surgical-risk patients
The EVA-3S (Endarterectomy versus Angioplasty in
Patients with Symptomatic Severe Carotid Stenosis)
trial randomly assigned 527 symptomatic (≥60%) low-
or average-surgical risk patients to CAS or CEA [34]. The
30-day incidence rates of stroke or death were 3.9% for
CEA and 9.6% for CAS. Early in the trial, the use of
embolic protection devices (EPDs) was not required and
this generated a stroke rate of 25% (5 of 20). This caused
the trial to be stopped and restarted with EPD use
required. The inexperience of the interventionalists,
particularly the surgical operators, is a significant limita-
tionof thisstudy. Thepatients inEVA-3Shadrisk profiles
similar to those of CREST (Carotid Revascularization
Endarterectomy Versus Stenting Trial) roll-in patients,
but CREST required at least 20 cases of carotid stent
experience with audited results and mandated the use of
an EPD. In contrast to the high rate of stroke and death in
EVA-3S, the most recent report of 1,246 lead-in patients
demonstrated a 30-day stroke and death rate of 5.6% for
symptomatic CREST lead-in registry patients [35].
Physician specialty-specific data from CREST were
presented by Donald V Heck at the 2009 Society of
NeuroInterventional Surgery meeting. He reported
30-day stroke and death by subspecialty during the
lead-in phase of the CREST trial. Subspecialty training in
catheter-based techniques – cardiology, radiology, and
neuroradiology – had a statistically lower event rate than
did the non-catheter-based specialty of vascular surgery.
Vascular surgeons had a statistically significant, twofold
increase in their complication rate (stroke and death)
compared with the physicians trained in catheter-based
techniques.
The SPACE (Stent-Supported Percutaneous Angioplasty
of the Carotid Artery versus Endarterectomy) trial
showed no difference between CEA and CAS in average
surgical risk in symptomatic patients with optional use
of EPDs [36]. The 30-day stroke and death rates were
Figure 2. Outcomes for CAPTURE and EXACT clinical trials in
patients younger than 80 years of age
CAPTURE, Carotid Acculink/Accunet Post-Approval Trial to Uncover
Unanticipated or Rare Events; EXACT, Emboshield and Xact Post-Approval
Carotid Stent Trial.
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or statistically different. One drawback of the study was
the lack of EPD use in 73% of the study subjects. After 2
years of follow-up, there continued to be no difference in
outcomes between CEA and CAS; however, for patients
who were younger than 69 years of age at randomiza-
tion, CAS was significantly better (30-day stroke and
death and ipsilateral stroke for 2 years; 4.8%) compared
with CEA (8.0%; P < 0.005) [37,38].
A major impact on the field has been made with proximal
embolic occlusion (PEO) devices by lowering post-
procedural complication rates [39]. These PEO devices
have an advantage in that when the carotid lesion is
crossed with a guidewire for the entire procedure, no
antegradeflowoccurs,thusthe patient is protected against
procedure-related emboli. A recent trial reported a 1.4%
30-day stroke and death rate with a PEO in 1,288
consecutive patients [40]. The risks of 30-day stroke and
death were less than 1% in asymptomatic patients and
near 3% in symptomatic patients [40].
Implications for clinical practice
High risk for surgery
There now exists the highest level of evidence (AHA/ACC
class I, level of evidence A) that there is clinical equipoise
betweenCASandCEAforpatientsatincreasedsurgicalrisk
for CEA. This applies to both symptomatic and asympto-
matic patients with anatomic or comorbid features that
place them at increased risk for CEA. This conclusion is
supported and reinforced by the three recently published
post-market surveillance trials (CAPTURE-2, EXACT, and
SAPPHIRE WW) [20,23]. In these patients at high risk for
CEA (both symptomatic and asymptomatic patients)
younger than 80 years of age, the AHA benchmark levels
were met. The current recommendation for patients at
increased risk for CEA is that CAS should be considered a
reasonable alternative for stroke prevention.
Usual or average risk for surgery
There is no consensus regarding the relative outcomes of
CAS versus CEA in average-risk patients. Clinical trials in
this patient population over the past 2 years have ranged
from EVA-3S, which strongly favored CAS over CEA, to
the most recently reported PEO system with extremely
low stroke and death rates in both symptomatic and
asymptomatic patients. The SPACE trial split the
difference, showing a benefit for CAS in patients younger
than 69 years old and an advantage for CEA in older
patients. The results of CREST, a large randomized
controlled trial in average-surgical-risk patients, will be
reported within the next few months and will go a very
long way toward informing our recommendations in the
low- or usual-surgical-risk population.
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